These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 31583919)

  • 1. Blinatumomab: a novel therapy for the treatment of non-Hodgkin's lymphoma.
    Bukhari A; Lee ST
    Expert Rev Hematol; 2019 Nov; 12(11):909-918. PubMed ID: 31583919
    [No Abstract]   [Full Text] [Related]  

  • 2. Blinatumomab for the treatment of B-cell lymphoma.
    Oak E; Bartlett NL
    Expert Opin Investig Drugs; 2015 May; 24(5):715-24. PubMed ID: 25739952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting non-Hodgkin lymphoma with blinatumomab.
    Sanders S; Stewart DA
    Expert Opin Biol Ther; 2017 Aug; 17(8):1013-1017. PubMed ID: 28532177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study.
    Goebeler ME; Knop S; Viardot A; Kufer P; Topp MS; Einsele H; Noppeney R; Hess G; Kallert S; Mackensen A; Rupertus K; Kanz L; Libicher M; Nagorsen D; Zugmaier G; Klinger M; Wolf A; Dorsch B; Quednau BD; Schmidt M; Scheele J; Baeuerle PA; Leo E; Bargou RC
    J Clin Oncol; 2016 Apr; 34(10):1104-11. PubMed ID: 26884582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy.
    Goebeler ME; Bargou R
    Leuk Lymphoma; 2016 May; 57(5):1021-32. PubMed ID: 27050240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blinatumomab for the treatment of adult acute lymphoblastic leukemia.
    Dahl J; Mace M; Kantarjian H; Jabbour E
    Drugs Today (Barc); 2015 Apr; 51(4):231-41. PubMed ID: 26020065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blinatumomab, a Bispecific T-cell Engager (BiTE(®)) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its Implications.
    Zhu M; Wu B; Brandl C; Johnson J; Wolf A; Chow A; Doshi S
    Clin Pharmacokinet; 2016 Oct; 55(10):1271-1288. PubMed ID: 27209293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma.
    Viardot A; Goebeler ME; Hess G; Neumann S; Pfreundschuh M; Adrian N; Zettl F; Libicher M; Sayehli C; Stieglmaier J; Zhang A; Nagorsen D; Bargou RC
    Blood; 2016 Mar; 127(11):1410-6. PubMed ID: 26755709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blinatumomab: A First-in-Class Bispecific T-Cell Engager for Precursor B-Cell Acute Lymphoblastic Leukemia.
    Buie LW; Pecoraro JJ; Horvat TZ; Daley RJ
    Ann Pharmacother; 2015 Sep; 49(9):1057-67. PubMed ID: 26041811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical applications and safety evaluation of the new CD19 specific T-cell engager antibody construct blinatumomab.
    Wilke AC; Gökbuget N
    Expert Opin Drug Saf; 2017 Oct; 16(10):1191-1202. PubMed ID: 28825327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of bispecific T-cell engager (BiTE) antibody blinatumomab for the treatment of relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin's lymphoma: a systemic review and meta-analysis.
    Yu J; Wang W; Huang H
    Hematology; 2019 Dec; 24(1):199-207. PubMed ID: 30479190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Harnessing T cells to fight cancer with BiTE® antibody constructs--past developments and future directions.
    Klinger M; Benjamin J; Kischel R; Stienen S; Zugmaier G
    Immunol Rev; 2016 Mar; 270(1):193-208. PubMed ID: 26864113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia.
    Wu J; Fu J; Zhang M; Liu D
    J Hematol Oncol; 2015 Sep; 8():104. PubMed ID: 26337639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies.
    Viardot A; Locatelli F; Stieglmaier J; Zaman F; Jabbour E
    Ann Hematol; 2020 Oct; 99(10):2215-2229. PubMed ID: 32856140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bispecific Antibodies for Non-Hodgkin Lymphoma Treatment.
    Bock AM; Nowakowski GS; Wang Y
    Curr Treat Options Oncol; 2022 Feb; 23(2):155-170. PubMed ID: 35182296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma.
    Doraiswamy A; Shah MR; Bannerji R
    Curr Hematol Malig Rep; 2021 Feb; 16(1):72-81. PubMed ID: 33619641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDA Supplemental Approval: Blinatumomab for Treatment of Relapsed and Refractory Precursor B-Cell Acute Lymphoblastic Leukemia.
    Pulte ED; Vallejo J; Przepiorka D; Nie L; Farrell AT; Goldberg KB; McKee AE; Pazdur R
    Oncologist; 2018 Nov; 23(11):1366-1371. PubMed ID: 30018129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blinatumomab: a historical perspective.
    Nagorsen D; Kufer P; Baeuerle PA; Bargou R
    Pharmacol Ther; 2012 Dec; 136(3):334-42. PubMed ID: 22940266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of bispecific T-cell engager blinatumomab and the potential to improve leukemia-free survival in B-cell acute lymphoblastic leukemia.
    Ribera JM
    Expert Rev Hematol; 2017 Dec; 10(12):1057-1067. PubMed ID: 29082835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory B-cell malignancies: a narrative review with focus on diffuse large B-cell lymphoma.
    Zinzani PL; Minotti G
    J Cancer Res Clin Oncol; 2022 Jan; 148(1):177-190. PubMed ID: 34741682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.